REVIEW

Anti-retroviral drugs: current state and development in the next decade

Xingquan Zhang

Division of Infectious Diseases, Department of Medicine, School of Medicine, University of California, San Diego, CA 92093, USA

Received 2 December 2017; received in revised 12 January 2018; accepted 21 January 2018

KEY WORDS
Antiretroviral drugs; Long-acting formulations; Attachment inhibitors; Maturation inhibitors; Nanomedicine

Abstract  The pace of discovery of new antiretroviral (ARV) drugs has slowed, although the efficacy and safety of once-daily fixed dose combinations have been extensively investigated. Several traditional ARV drugs remain in phase III clinical trials. This review summarizes current information on ARV drugs in phase III clinical trials and focuses on the development of ARV drugs in the next decade.

© 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

By the end of 2017, United States Food and Administration (US FDA) had approved 43 anti-retroviral drugs for clinical use which include 29 single-tablets and 14 fixed-dose combinations (FDCs). The intensity of the search for novel antiretroviral (ARV) compounds has slowed over the last 10 years and several traditional agents are still in phase III clinical trials. In the next decade, to improve drug safety, adherence and efficacy, the development of new anti-HIV-1 drugs will focus on long-acting formulations, oral attachment inhibitors, maturation inhibitors and new initiatives to cure the disease.

In the first decade of ARV drug therapy, these agents did not fundamentally change the destiny of those with HIV infection, although they could decrease virus load, increase CD4+ cell number and prolong survival over the short term. The major shortcomings were drug toxicity, drug resistance and high drug cost. Combination-based ARV therapy (ART) was introduced in 1996, which led to effectively sustained HIV suppression, significantly recovered immune function, markedly improved clinical symptoms and notably extended lifespan. In the third decade, with further development of ARV drugs and the availability of multiple ART regimens and FDCs, acquired immune deficiency syndrome (AIDS) has become a chronic, manageable and infectious disease. It is noted that in the last several years, instead of the discovery of new ARV drugs, development of effective and well-tolerated once-daily FDCs has been extensively investigated, but several traditional ARV drugs remain in phase III clinical trials. This review introduces current ARV drugs in phase III clinical trials and summarizes the development of ARV drugs over the next decade. All of the 43 FDA-approved drugs are listed here, but additional specialized reviews will be required to address new trends towards the cure of this disease.

2. Anti-retroviral drugs approved by FDA

The first AIDS cases were reported in 1981 in United States.1-3. The human immunodeficiency virus (HIV) was defined as etiologic microorganism in 1983.3,4. Just four years later, the first HIV medicine Zidovudine was approved by US FDA and quickly opened the new era for anti-retroviral chemotherapy. In the following thirty years, the FDA approved a total of 43 anti-retroviral drugs including 29 single-tablets and 14 FDCs therapeutics. These agents are classified into eight categories of ARV drugs: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), fusion inhibitors (FIs), entry inhibitors (EIs), pharmacokinetic enhancers (PEs) and fixed-dose combinations (FDCs, Table 1).5-7.

3. Classical ARV drugs in phase III clinical trials

3.1. Tenofovir alafenamide (TAF)

TAF is a nucleotide transcriptase inhibitor (Fig. 1). Tenofovir disoproxil (TDF), a new produg of tenofovir, has a similar structure and is in clinical use. Initially TAF was designed to improve TDF-induced renal and bone toxicity. TAF has achieved 50% effective concentrations (EC50) at 11.0 and 9.7 nmol/L in CD4+ T cells and macrophage, respectively, and decrease of plasma tenofovir by 90%. As compared with TDF, TAF demonstrated several important improvements. The drug can be formulated into small tablets of FDCs, has a low manufacturing cost, and shows highly reduced kidney and bone toxicity. Therefore, TAF is becoming a preferred substitute for TDF with better efficacy. Several clinical studies of TAF combinations, including elvitegravire/cobicistat/emintricable/TAF (E/C/F/TAF), rilpivirine/ emtricitabine/TAF (R/F/TAF) and emtricitabine/TAF (FTAF) were reported on November 23, 2015, March 1, 2016 and April 25, 2016.

Phase III open-label studies have evaluated the safety of E/C/F/TAF in virologically-suppressed adults with mild-to-moderate renal impairment and in treatment-naïve 12–17 year olds.9. Whereas E/C/F/TDF is typically reserved for patients with creatinine clearance (CrCl) of at least 70 mL/min, E/C/F/TAF can be used with a pre-treatment estimated CrCl of as low as 30 mL/min. Phase III randomized, double-blind clinical trials evaluating the safety and efficacy of switching to R/F/TAF in HIV-positive individuals who are virologically suppressed by either R/F/TDF or efavirenz/F/TDF (EVF/TDF) are under investigation10. In other phase III studies, 668 and 330 HIV-1 positive patients were recruited in F/TAF and F/TDF groups separately. Through week 48, the success cases of virological inhibition (HIV-1 RNA <50 copies per mL) were maintained in 314 (94%) of patients in the F/TAF group compared with 307 (93%) in the F/TDF group (a difference of 1.3%, 95% CI –2.5 to 5.1), indicating the non-inferiority of F/TAF to F/TDF. Seven patients in F/TAF (2%) and three (1%) in the F/TDF group discontinued treatment due to adverse events. There were no cases of proximal tubulopathy reported in these studies.11.

3.2. Doravirine

Doravirine is a highly specific non-nucleoside reverse transcriptase inhibitor (Fig. 1).12,13. The half maximal inhibitory concentrations (IC50) are only 12, 9.7 and 9.7 nmol/L against the wild type HIV (WT) and 103 N and Y181C reverse transcriptase (RT) mutants, respectively. Doravirine exhibited consistent anti-HIV activities against 10 different HIV-1 subtype RT mutants, suggesting that doravirine is superior overall to that efavirenz and comparable to that of etravirine (ETR) and RPV. A two-drug in vitro combination study reported that doravirine had no antagonistic actions in the antiviral activity of 18 other FDA-licensed anti-HIV drugs. In vivo, doravirine demonstrated robust antiviral activity and good tolerability. Data from a 48 week phase II clinical trial showed that virologic suppression (<40 copies/mL) rates were achieved in 84% of inpatients with viral loads >100,000 copies/mL. In addition, drug-related adverse events, including diarrhea, dizziness, and abnormal dreams, were infrequent in the dorvirine group vs. the EFV group (56.5% versus 31.5%). Doravirine is currently undergoing its phase III clinical development.

3.3. Bictegravir (BIC, GS-9883)

BIC14 is a novel unboosted HIV-1 integrase strand inhibitor (Fig. 1). It inhibits HIV replication in both T-cells lines and in primary human T lymphocytes, with EC50 values ranging from 1.5 to 2.4 nmol/L. In addition, in vivo efficacy of BIC demonstrates synergy of anti-HIV effects in vitro when combined with TAF, emtricitabine and darunavir. BIC is showing an...
improved resistance profile compared to the INSTI raltegravir and elvitegravir, and was comparable to that of dolutegravir, against nine INSTI-resistant site-directed HIV-1 mutants.

Although the BIC/F/TAF combination is currently being tested in phase III clinical trials, no data from completed phase I or ongoing phase II trials has been reported. Phase III trials of BIC/F/TAF include two head-to-head comparisons with dolutegravir plus F/TAF in treat-naïve adults, with each study enrolling 600 participants in the US, Canada and other countries. Three switch phase III studies are also under evaluation, including the safety and efficacy of switching from dolutegravir plus abacavir/lamivudine (ABC/3TC) to BIC/F/TAF, a switch from boosted atazanavir or darunavir plus either F/TDF or ABC/3TC, and a switch in a cohort comprised of HIV-positive women to all in virologically suppressed participants.

4. ARV drugs in the pipeline for the next 10 years

4.1. Long-acting ARV formulation

Currently, ARV drugs are administered through lifelong daily oral regimens. However, poor compliance is often observed with ARVs in HIV-1 patients. When suboptimal compliance occurs, circulating ARVs are insufficient to inhibit viral replication, thereby increasing the chances of viral mutation and drug

---

**Table 1** US FDA approval of HIV medicines.

| Year | Drug                  | Year | Drug                  |
|------|-----------------------|------|-----------------------|
| 1987 | Zidovudine (NRTI)     | 2004 | Epzicom (FDC), Truvada (FDC), Cobicistat (PE), Fosamprenavir (PI) |
| 1991 | Didanosine (NRTI)     | 2005 | Tipranavir (PI)       |
| 1992 | Zalcitabine (NRTI)*   | 2006 | Darunavir (PI), Atripla (FDC) |
| 1994 | Stavudine (NRTI)      | 2007 | Maraviroc (EI)        |
| 1995 | Lamivudine (NRTI), Saquinavir (PI) | 2008 | Raltegravir (INSTI)   |
| 1996 | Indinavir (PI), Nevirapine (NNRTI), Ritonavir (PI) | 2011 | Complera (FDC), Virmune XR (NNRTI), Rilpivirine (NNRTI) |
| 1997 | Combivir (FDC), Delavirdine (NNRTI), Nelfinavir (PI) | 2012 | Strivid (FDC)         |
| 1998 | Abacavir (NRTI), Efavirenz (NNRTI) | 2013 | Dolutegravir (INSTI)  |
| 1999 | Amprenavir (PI)*      | 2014 | Cobicistat (PE), Triumeq (FDC) |
| 2000 | Didanosine EC (NRTI), Kaletra (FDC), Trizivir (FDC) | 2015 | Evotaz (FDC), Genvoya (FDC), Prezobix (FDC) |
| 2001 | Tenofovir DF (NRTI)   | 2016 | Descovy (FDC), Oflexy (FDC) |
| 2003 | Atazanavir (PI), Emtricitabine (NRTI), Enfuvirtide (FI) | 2017 | Descovy (FDC), Oflexy (FDC) |

*Drugs are no longer recommended for use in the United States by the HHS HIV/AIDS medical practice guidelines.

---

**Figure 1** Classical ARV drugs in phase III clinical trials. (A) Tenofovir alafenamide (GS-7340, Vemlidy, C₂₃H₂₉N₆O₅P), a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. (B) Doravirine (MK-1439, C₁₇H₁₁ClF₃N₅O₃), a non-nucleoside reverse transcriptase inhibitor. (C) Bictegravir (BIC, GS-9883, C₂₁H₁₈F₃N₃O₅), an integrase inhibitor.

**Figure 2** ARV drugs in the pipeline for the next 10 years. (A) Rilpivirine hydrochloride (Edurant; TMC278 hydrochloride, C₂₂H₁₉ClN₆), a second-generation NNRTI. (B) Cabotegravir (S/GSK1265744 or GSK744, C₁₉H₁₁ClF₃N₆O₃), an integrase inhibitor. (C) Fostemsavir, BMS-663068, C₂₅H₂₆N₇O₈P), the phosphonooxymethyl prodrg of BMS-626529, a novel small-molecule attachment inhibitor. (D) Temsavir (BMS-626529, C₂₄H₂₃N₇O₄), a novel small-molecule attachment inhibitor. (E) Bevirimat, BVM (MPC-4326, PA-457, C₃₆H₅₆O₆), the first maturation inhibitor. (F) BMS-955176 (C₄₂H₆₂N₂O₄S), the second generation HIV maturation inhibitor.
resistance. Thus, long-acting, effective ARVs circumvent the limitations of daily oral regimens, and provide long-lasting ARV efficacy in either pre-exposure or post-exposure prophylaxis.

RPV is a second-generation NNRTI that has a longer half-life and reduced toxicity compared with previous NNRTIs (Fig. 2). It has been widely used as a single ARV or a combination component for HIV therapy at the oral 25 mg dose. To further extend its half-life, long-acting RPV has been investigated recently. Single dose administration of the long-acting RPV achieved constant drug retention in plasma for more than 6 months and 100% drug bioavailability in a pharmacokinetic study. In one phase I study of the long-acting formulation with 60 healthy HIV-negative volunteers, intramuscular or abdominal subcutaneous administered RPV was retained in the plasma for 12–26 weeks at more than 10 ng/mL. Another study of long-acting RPV reported that maximum drug concentrations of 34, 82, and 160 ng/mL at 300, 600 and 1200 mg treatment, respectively, following intramuscular administration. The half-life of this RPV formulation was more than 3 months. All of these reports indicate that the long-acting formulation of RPV is devoid of adverse drug events. More importantly, no hypersensitivity reactions or EGG abnormalities were observed. Currently, there is an ongoing phase II clinical trial for RPV.

4.1.1. Cabotegravir
Cabotegravir (Fig. 2) is an HIV-1 integrase strand transfer inhibitor. The long-acting injectable formulations of cabotegravir are being studied for clinical development. It is known that cabotegravir has superior ARV activity with an IC50 of 0.22 and 0.34 μmol/L against HIV-1Bal and HIV-1NL43. This novel integrase inhibitor specifically binds to plasma albumin protein leading to a protein-adjusted IC50 of 166 ng/mL with an oral plasma half-life of 40 h. In a phase II study, once daily treatment with 5 or 30 mg cabotegravir for 10 days demonstrated excellent antiviral efficacy, with a decrease of plasma HIV-1 RNA for 2.2–2.3 log10 copies/mL. Interestingly, the long-acting formulation of cabotegravir is packaged into crystal nanoparticles. Following subcutaneous or intramuscular administration, long-acting cabotegravir is slowly absorbed into blood from tissue injection sites. In a phase I trial, the long-acting injectable nanosuspension of cabotegravir were evaluated following 100–800 mg intramuscular and 100–400 mg subcutaneous injections. The therapeutically relevant plasma concentrations were achieved within 3 days after drug injection and remained in circulation from 21–50 days. Up to now, no severe injectable site reactions (ISRs), or ISR-related withdrawals have been reported for this long-acting cabotegravir formulation.

In addition, a combination of cabotegravir with RPV is being tested as a double-drug regimen for the HIV therapy. The phase II investigation was performed to evaluate the efficacy and safety with the oral combination of cabotegravir+RPV in HIV-1-infected patients. At 48 week, 82% of participants across the three cabotegravir+RPV arms achieved the primary endpoint, with similar response rates across cabotegravir doses, relative to a 71% response rate in the EFV control arm. Although follow-up viral load data are not yet available, cabotegravir+RPV was generally well tolerated with no drug-related serious adverse events and few adverse event-related withdrawals.

4.1.2. Nanoformulated ART (NanoART)
NanoART is another long-acting strategy for extending the half-life of ARV drugs for HIV treatment. In the past ten years, nanotechnology has been employed to manipulate the formulation of the traditional ARV drug at the level of drug size, shape, and surface charge. Several studies have shown that solid crystal nanoparticles can remarkably increase drug level in blood circulation and lymphoid tissue. This nanoART, which selectively targets mononuclear macrophage as a cellular drug depot, delivers ARVs such as atazanavir to tissue reservoirs. This macro-phase-mediated drug delivery facilitates long-acting drug release and achieves viral suppression for more than two weeks or even one month after single dose regimen. It was reported that the advanced nanoART, which is coated with folic acid receptors, can improve drug concentration tenfold (compared to the first generation of nanoART) in serum and lymph node over two weeks with one injection. Moreover, the novel mixed-lineage kinase 3 inhibitor (URMC-099) was observed to slow down the release of nanoART, leading to significant increases in the long-acting efficacy of nanoART. URMC-099 was originally discovered as an anti-neuroinflammation drug for the treatment of HIV-1 associated neurocognitive disorders (HAND) and Alzheimer's disease. However, the combination of anti-neuroinflammation drug URMC-099 and ARV drug nanoART has created a novel long-acting strategy for HIV eradication and further improves the cell-based drug delivery platform direct for translational application.

4.2. New attachment inhibitors
HIV-1 entry into target cells involves viral attachment, co-receptor-engagement and fusion. New attachment inhibitors which target each step of the entry process have been developed recently. Postemavir (BMS-663068, Fig. 2) is the phosphonoxyethyl produg of BMS-626529, a small molecule attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells. Postemavir inhibits HIV-1LA infected at EC50 of 0.7 mM/L. In a study of a cohort of laboratory strains, it exhibited an EC50 of 0.01 mM/L against the most susceptible HIV and an EC50 value of 2 μM/L against the least susceptible HIV. In addition, the virus was found to be resistant to other HIV entry inhibitors, such as enfuvirtide (ENF).

Table 2: Entry inhibitors that have reached late stage clinical trials.

| Inhibitor         | Development status | Drug class                   | Action against entry stage |
|-------------------|--------------------|------------------------------|-----------------------------|
| BMS-663068        | Phase III          | Small molecular              | Binds to region with CD4    |
| Ibalmuzab         | Phase III          | Post-attachment inhibitor (mAb) | Binds to CD4               |
| Aplaviroc         | Phase Ia and III   | Small molecularCCR5 antagonist| Binds to CCR5              |
| Cenicriviroc      | Phase Ia and III   | Small molecularCCR5 and CCR2 antagonist | Binds to CCR5 and CCR2 |
| Sifuvirtide       | Early phase        | Peptides fusion inhibitor    | Binds to gp41              |
and ibalizumab, and maintained susceptibility to BMS-62652937. A phase III study of fostemsavir was initiated in February 2015.

Ibalizumab (TMB-355, also known as TNX-355) is a non-immunosuppressive monoclonal antibody that targets membrane protein CD4, the primary receptor for HIV entry. This MAb is a potent inhibitor of HIV-1 in vitro and shows synergy when combined with HIV gp120 antibodies or the fusion inhibitor enfuvirtide. It does not interfere with antigen presentation of immune cells23,30,39. In phase I studies30, intravenous injection of ibalizumab decrease the plasma HIV-1 RNA for up to 1.5 log10-fold at Day 14–21 after single dose treatment. A phase II study40 of ibalizumab reported that ibalizumab plus an optimized background regimen resulted in further decrease in plasma HIV-1 RNA compared to the background regimen alone. A subsequent phase II study also demonstrated that intravenous infusion of ibalizumab every two weeks, leading to significant viral load reduction over 24 weeks. Currently, heavily treatment-experienced patients have been enrolled in the nonrandomized arm of the phase III study to evaluate the combination treatment of fostemsavir and ibalizumab37.

4.3. The maturation inhibitors

The maturation inhibitors have been developed as a novel category of ARV drugs which targets the final step of HIV virion assembly and packaging. Unlike the PI, HIV maturation inhibitors directly bind to the HIV capsid protein and inhibit viral protein assembly into infectious HIV particle. Maturation inhibition leads to the production of noninfectious, immature virus particles. No other class of drugs shares this mechanism of action. Thus, maturation inhibitors retain inhibitory activity against HIV strains that are resistant to other classes of drugs. Several clinical trials with maturation inhibitors are underway.

Bevirmat (BVM, Fig. 2)12 is the first maturation inhibitor, which preferentially inhibits cleavage of SP1 from the C-terminus of HIV capsid (CA) protein. BVM has strong anti-HIV-1 IIIB activity with IC50 of 1.3 nmol/L. Several studies have demonstrated the following: 1. BVM induces the accumulation of the unspliced CA-SP1 intermediate in both intracellular space and virus-associated protein fractions from HIV-1-infected cells; 2. BVM has no effect on divergent sequences at the CA-SP1 junction; 3. The majority of BVM drug-resistance mutations are found on the CA-PS1 junction or within SP1.

BMS-955176 (Fig. 2)13 and its backup candidate BM986173 represent second generation maturation inhibitors. BMS-955176 has a maximum reduction of viral load of 1.7 log10 on a 40-mg once daily dose. This compound, unlike the first generation of maturation inhibitors, exhibits potent ARV activity against wild type HIV or HIV with baseline Gag polymorphisms. In a ten-day study of BMS-955176 monotherapy, similar antiviral activity was found in subjects with either wild type HIV or HIV with Gag polymorphisms, and in subjects with either HIV-1 subtype B or subtype C. In another study, evaluation of BMS-95166 in combination with atazanavir (with or without ritonavir boosting) showed similar maximum median declines in viral loads through Day 42. Until now, it has been found that BMS-955176 is generally well tolerated, with no adverse events requiring discontinuation. Phase II studies are under investigation including a safety and efficacy comparison with EFV (with both BMS-176 and EFV combined with TDF/FTC) and an open-label evaluation of BMS-955176 combined with dolutegravir and atazanavir in treatment-experienced adults. Pharmacokinetics and additional safety trials are also ongoing.

5. Conclusions

In the last ten years, ART research has switched from a focus on new drug development to optimization of current fixed dose combinations32,37. To approach the 90-90-90 goals of World Health Organization (WHO) by 2020 (90% of HIV-1 infected people diagnosed; 90% of those who are diagnosed started on ART; 90% of those on ART virally suppressed), current FDCs are still considered as the major therapeutic agents to fight against HIV infection. Thus, the development of long-acting formulations, oral attachment inhibitors and maturation inhibitors is urgently needed and essential for improvement of HIV therapy in the coming decade.

Acknowledgments

The author acknowledge Dr. Robert Schooley for the editorial assistance.

References

1. Centers for Disease Control and Prevention. Pneumocystis pneumonia —Los Angeles. Mmwr Morb Mortal Wkly Rep 1981;30:250–2.
2. Centers for Disease Control. Kaposi's sarcoma and pneumocystis pneumonia among homosexual men—New York City and California. MMWR Morb Mortal Wkly Rep 1981;30:305–8.
3. Klatzmann D, Barre-Sinoussi F, Nugeyre MT, Danquet C, Vilmer E, Griscelli C, et al. Selective tropism of Lymphadenopathy Associated Virus (LAV) for helper-inducer T lymphocytes. Science 1984;225:59–63.
4. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984;224:500–3.
5. Horn T, Collins S. The antiretroviral pipeline. New York: TAG; 2016.
6. Kiyota T, Morrison CM, Tu G, Dyavarshetty B, Weir RA, Zhang G, et al. Presenilin-1 familial Alzheimer's disease mutation alters hippocampal neurogenesis and memory function in CCL2 null mice. Brain Behav Immun 2015;49:311–21.
7. AIDSinfo Fact Sheet. FDA-Approved HIV Medicines. 2017. Available from: (https://aidsinfo.nih.gov/understanding-hiv-aids/infographics/25/fda-approval-of-hiv-medicines).
8. Gallant JE, Darer ES, Raffi F, Brinson C, Ruane P, DesJees E, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV 2016;3:e158–65.
9. Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicitatib and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a Single-Arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr 2016;71:530–7.
10. Clinical Trials. Gov. Study to evaluate switching from a regimen consisting of efavirenz/emtricitabine/tenofovir disoproxil fumarate (EfV/FTC/TDF) Fixed Dose Combination (FDC) to emtricitabine/rilpivirine/tenofovir alafenamide (FTC/RPV/TAF) FDC in virologically-suppressed, HIV-1 infected adults. [Updated 11.12.17]. Available from: (https://clinicaltrials.gov/ct2/show/NCT02345226).
11. Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 2014;67:52–8.
12. Lai MT, Feng M, Falgueyret JP, Tawa P, Witmer M, DiStefano D, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2014;58:1653–63.

13. Morales-Ramirez J.O., Gatell J.M., Hagins D.P., Thompson M., Arasteh K., Hoffmann C., et al. Safety and antiretroviral effect of MK-1439, a novel NNRTI (+FTC/TDF) in ART-naive HIV-infected patients. In: Proceedings of Conference on Retroviruses and Opportunistic Infections (CROI); Mar 3-6; Boston, Massachusetts: CROI, 2014.

14. Tsang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother 2016;60:7086–97.

15. Clinical Trials. Gov. Safety and efficacy of switching to A FDC of B/F/TAF from E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in virologically suppressed HIV-1 infected women. [Updated 06.11.17]. Available from: (https://www.clinicaltrials.gov/ct2/show/NCT02652624).

16. Goebel F, Yakolev A, Pozniak Al, Vinogradova E, Boogaerts G, Hoetelmans R, et al. Short-term antiretroviral activity of TMC278—a novel NNRTI-in treatment-naive HIV-1-infected subjects. AIDS 2006;20:1721–6.

17. Baert L, Van’T Klooster G, Dries W, François M, Wouters A, Bastanie E, et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm 2009;72:502–8.

18. Verloes R, Deleu S, Niemeijer N, Crauwels H, Meyvisch P, Williams P. Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers. HIV Med 2015;16:477–84.

19. Jackson AG, Else L, Mesquita PM, Egan D, Back DJ, Karolia Z, et al. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther 2014;96:314–23.

20. Clinical Trials. Gov. Switch Study to evaluate the safety and efficacy of entrectinib/rilpivirine/tenofovir alafenamide (FTC/ RPV/TAF) fixed dose combination (FDC) in HIV-1 positive adults who are virologically suppressed on entrectinib/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF). [Updated 08.12.17]. Available from: (https://clinicaltrials.gov/ct2/show/NCT03245525).

21. Margolis DA, Boffito M. Long-acting antiviral agents for HIV treatment. Curr Opin HIV AIDS 2015;10:246–52.

22. Margolis DA, Brinson CC, Smith GH, de Vente J, Hagins DP, Eron JJ, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis 2015;15:1145–55.

23. Henrich TJ, Kuritzkes DR. HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol 2013;3:51–7.

24. Gendelman HE, Balogh LP, Bawa R, Bradbury M, Chang EH, Chiu W, et al. Proceedings of the 4th annual meeting of the American society for nanomedicine. J Neuroimmune Pharm 2014; 9 Suppl 1:S1–3.

25. Gorantla S, Zhang G, Dash PK, et al. Nanomedicines and antiretroviral therapy. J Neuroimmune Pharm 2014;9:21–2.

26. Nowacke A, Zhang G, McMillan J, Kiyota T. Nanomedicine and neurodegenerative disorders. In: Preedy VR, Hunter RJ, editors. Nanomedicine in health and disease. Boca Raton: CRC Press; 2011. p. 377.

27. Li T, Gendelman HE, Zhang G, Puligujja P, McLennan JM, Bronich TK, et al. Magnetic resonance imaging of folate acid-coated magnetoparticle nanoparticles reflects tissue biodistribution of long-acting antiretroviral therapy. Int J Nanomed 2015;10:3779–90.

28. Puligujja P, Balkundi SS, Kendrick LM, Balbridge HM, Hilaire JR, Bade AN, et al. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials 2015;41:141–50.

29. Guo D, Zhang G, Wysocki TA, Wysocki BI, Gelbard HA, Liu XM, et al. Endosomal trafficking of nanofomedulated antiretroviral therapy facilitates drug particle carriage and HIV clearance. J Virol 2014;88:9504–13.

30. Zhang G, Dash PK, Wiederin JL, et al. Urmc-099: a mixed-lineage kinase-3 (MLK3) inhibitor with the potential to eradicate human immunodeficiency virus infection. J Neuroimmun Pharm 2013;8:437.

31. Zhang G, Guo D, Dash PK, Araúga M, Wiederin JL, Haverland NA, et al. The mixed lineage kinase-3 inhibitor URMCI-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine 2016;12:109–22.

32. Dong W, Embury CM, Lu Y, Whitmire SM, Dyavarshetty B, Gelbard HA, et al. The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation. J Neuroinflammation 2016;13:184.

33. Yang J, Hu D, Xia J, Liu J, Zhang G, Gendelman HE, et al. Enhancement of NMDA receptor-mediated excitatory postsynaptic currents by gp120-treated macrophages: implications for HIV-1-associated neuropathy. J Neuroimmune Pharm 2013;8:921–33.

34. Kiyota T, Gendelman HE, Weir RA, Higgins EE, Zhang G, Jain M. CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. Neurobiol Aging 2013;34:1060–8.

35. Nowicka-Sans B, Gong YF, McAuliffe B, Dicker I, Ho HT, Zhou N, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodruk BMS-663068. Antimicrob Agents Chemother 2012;56:3498–507.

36. Nettiles RE, Schirrmann D, Zhu L, Stonier M, Huang SP, Chang I, et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis 2012;206:1002–11.

37. Li Z, Zhou N, Sun Y, Ray N, Lataille M, Hanna GJ, et al. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodruk BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors. Antimicrob Agents Chemother 2013;57:4172–80.

38. Zhang XQ, Sorensen M, Fung M, Schooley RT. Synergistic in vitro antiretroviral activity of a humanized monoclonal Anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob Agents Chemother 2006;50:2231–3.

39. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, et al. Antiretroviral activity of the Anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004;189:286–91.

40. Clinical Trials. Gov. Belizumab plus optimized background regimen in patient with multi-drug resistant HIV. [Updated 2017 Feb 8]. Available from: (https://clinicaltrials.gov/ct2/show/NCT02475629).

41. Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an Anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2009;53:450–7.

42. Martin DE, Salzwedel K, Allaway GP. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother 2008;19:107–13.

43. Regueiro-Reg A, Liu Z, Chen Y, Sin N, Sit SY, Swiderski JJ, et al. Discovery of BMS-955176, a second generation HIV-1 maturation inhibitor with broad spectrum antiviral activity. ACS Med Chem Lett 2016;7:658–72.

44. Hedrich WD, Hassan HE, Wang HB. Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B 2016;5:413–25.